Skip to main content
OpenTrials
Completed

NCT Number: NCT00455715

A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia

The study is a double-blind, placebo-controlled, random-order, single-dose crossover trial of sildenafil 50 & 100 mg added to stable antipsychotic treatment in schizophrenia patients to assess whether this PDE5 inhibitor improves cognitive functioning (including verbal memory, fluency, attention, spatial memory, motor speed, and executive function) and clinical symptoms (psychotic, negative, mood symptoms, and self-reports of side-effects).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

About this study

Specific Aims:

  • Evaluate the effects of single doses of sildenafil 50 & 100 mg compared to placebo on cognitive functioning, including verbal memory, fluency, attention, spatial memory, motor speed, and executive function.
  • Evaluate the effects of single doses of sildenafil 50 & 100 mg compared to placebo on psychotic, negative, and mood symptoms.
  • Assess self-reports of side effects of sildenafil 50 & 100 mg.

Location and Subjects:

25 adult outpatients with schizophrenia will be recruited from the Massachusetts General Hospital outpatient clinic or the Freedom Trail Clinic of the Lindemann Center. All research procedures will be performed at the Psychopharmacology Clinic of the Massachusetts General Hospital. Subjects must be English speaking because the cognitive battery has only been validated in English.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of schizophrenia, any subtype.
  • Age 18-65 years
  • Male or female
  • Clinically stable without a medication change within 4 weeks
  • Able to complete cognitive testing (must be English-speaking)
  • Willing to use appropriate birth control during study participation (if female)

Exclusion criteria

  • Active substance abuse or dependence
  • PDE 5 inhibitor taken within 24 hours of study drug
  • Currently taking a drug that inhibits hepatic cytochrome P450 3A4 (eg. Nefazadone, fluvoxamine, erythromycin, ketoconazole, itraconazole, cimetidine, saquinavir, ritonavir, St. John's wort, or grapefruit juice).
  • Currently taking drugs that induce P45 3A4 (eg. phenytoin, carbamezapine, Phenobarbital, rifampin)
  • Unstable medical disease
  • Significant cardiac disease
  • Bleeding disorder
  • Peptic ulcer disease
  • Hepatic impairment
  • Moderate or greater renal impairment
  • History of migraines
  • Currently taking nitrates or alpha blockers
  • Resting blood pressure < 90/50 or >140/90 mm.
  • History of intolerance to PDE5 inhibitors
  • History of inappropriate sexual behavior (eg, masturbation in public, stalking, assault)
  • History of priapism
  • Pregnant or lactating

Treatment and study plan

Sildenafil

Drug

1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.

Other names: Viagra

Primary outcomes

  1. Evaluate the effects of single doses of sildenafil 50 & 100 mg compared to placebo on cognitive functioning, including verbal memory, fluency, attention, spatial memory, motor speed, and executive function.

    Time frame: 12 days

Secondary outcomes

  1. Evaluate the effects of single doses of sildenafil 50 & 100 mg compared to placebo on psychotic, negative, and mood symptoms.

    Time frame: 12 days

  2. Side effects of sildenafil 50 & 100 mg as self-reported by subjects and as measured with vital signs.

    Time frame: 12 days

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Registry information

Important dates

Study start
2006
Primary completion
2007
Study completion
2008
First posted
Apr 4, 2007
Registry last updated
Jun 29, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.